We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Tristel Plc | LSE:TSTL | London | Ordinary Share | GB00B07RVT99 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-5.00 | -1.15% | 430.00 | 420.00 | 440.00 | 437.50 | 430.00 | 437.50 | 19,198 | 09:37:33 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Med, Dental, Hosp Eq-whsl | 36.01M | 4.46M | 0.0941 | 45.70 | 203.82M |
By Elena Vardon
Tristel on Monday said its ULT high-level disinfectant has gotten approval by the U.S. Food and Drug Administration for its immediate sale for use on endocavity ultrasound probes and skin surface transducers.
The manufacturer of infection-prevention products said it will launch the product in the U.S. market in October. The group is working with Parker Laboratories and established a manufacturing base in New Jersey to make the disinfectant, which it will distribute using Parker's network for the ultrasound market.
Its DUO intermediate level disinfectant is now registered in all U.S. states, the London-listed group added.
Write to Elena Vardon at elena.vardon@wsj.com
(END) Dow Jones Newswires
June 05, 2023 03:04 ET (07:04 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Tristel Chart |
1 Month Tristel Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions